Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:

Aurinia Pharm Ord (AUPH)

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Aurinia Announces PTAB Has Terminated Inter Partes Review Business Wire - Wed Jan 25, 12:00PM CST

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States’ Patent and Trademark Office has terminated the Inter Partes Review...

AUPH : 8.94 (-4.59%)
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office Business Wire - Tue Jan 24, 3:00PM CST

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has allowed a method of use patent application titled IMPROVED...

AUPH : 8.94 (-4.59%)
Why Shares of Aurinia Pharmaceuticals Soared This Week Motley Fool - Fri Jan 6, 3:49PM CST

A patent settlement and improved financials sent the stock soaring.

AUPH : 8.94 (-4.59%)
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results Business Wire - Fri Jan 6, 5:00AM CST

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its business performance. Preliminary unaudited net revenue for the three months and full year ended December...

AUPH : 8.94 (-4.59%)
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference Business Wire - Wed Jan 4, 3:05PM CST

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, is scheduled to present at the 41 st Annual J.P. Morgan...

AUPH : 8.94 (-4.59%)
Aurinia (AUPH) Soars 37.5%: Is Further Upside Left in the Stock? Zacks - Wed Jan 4, 3:47AM CST

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....

AUPH : 8.94 (-4.59%)
IMGN : 4.51 (-5.05%)
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Tue Jan 3, 3:55PM CST

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that the Company’s...

AUPH : 8.94 (-4.59%)
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals Business Wire - Tue Jan 3, 8:12AM CST

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announces it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd.,...

AUPH : 8.94 (-4.59%)
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Mon Dec 5, 2022

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that the Company’s...

AUPH : 8.94 (-4.59%)
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis Business Wire - Wed Nov 30, 2022

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced that the...

AUPH : 8.94 (-4.59%)

Barchart Exclusives

When will Soaring Egg Prices Come Down? Barchart - Mon Jan 30, 2:09PM CST
Last Week’s Moves Corn 683-6 (+2.63%) | Soybeans 1535-2 (+3.02%) | SRW Wheat 752-4 (+4.51%) KC Wheat 873-6 (+6.68%) | Live Cattle 163.350 (+1.74%) | Lean Hogs 86.525 (+1.26%) ______________________________________________________________________ Welcome to your weekly agriculture report, where we cover everything you’ll need to know for the week ahead. This week,... Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot